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Background: Patients with relapsed/refractory stage 4 high-risk neuroblastoma were enrolled on a phase I study
(NANT2004-03) of intravenous fenretinide emulsion. Pharmacokinetic samples were collected during and after the
infusion, and the levels were measured using an HPLC system. A likely case of a fatal drug interaction between
fenretinide, ceftriaxone, and acetaminophen is described, including the pharmacokinetics of fenretinide, laboratory
data, and post-mortem autopsy in a pediatric neuroblastoma patient treated on this study.
Case presentation: On Day 4 of a scheduled 5-day-infusion of intravenous fenretinide, the patient developed a
fever, acetaminophen was started, ceftriaxone initiated for possible bacteremia, and fenretinide level doubled
from 56 to 110 μM. Over the next three days, although blood cultures remained negative, the patient’s condition
deteriorated rapidly. Acute liver failure was diagnosed on Day 7, and the patient expired on Day 20 of fulminant
hepatic failure with associated renal, cardiac, and hemorrhagic/coagulation toxicities. Autopsy showed extensive
hemorrhagic necrosis of the liver, marked bile duct proliferation, and abundant hemosiderin, consistent with
cholestasis and drug toxicity.
Conclusions: After extensive review of patient data, the clinical course, and the literature, we conclude that
observed hepatic toxicity was likely due to a drug interaction between fenretinide and concomitant ceftriaxone and
acetaminophen. None of the other 16 patients treated on this study experienced significant hepatic toxicity.
Although the prevalence of cholestasis with ceftriaxone usage is relatively high, the potential drug interaction with
these concomitant medications has not been previously reported. Concomitant use of fenretinide, ceftriaxone, and
acetaminophen should be avoided.
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Ceftriaxone is a widely-used, semi-synthetic third gener-
ation cephalosporin antibiotic noted for its broad activity
spectrum, long plasma half-life, and relative paucity of
side effects. However, the association of ceftriaxone and
biliary ‘sludging’ (pseudolithiasis) is well documented.
[1-4]. Ceftriaxone is present in bile at 20- to 150-fold
higher concentrations than serum, is minimally metabo-
lized, and is excreted as a divalent anion that is calcium
sensitive [4]. It is speculated that the pseudolithiasis re-
sults from the combination of a hepatic effect, wherein
the liver secretes a biochemically abnormal bile, and a
gall-bladder effect, which provides the environment for
anion precipitation [4]. With rapid onset and disappear-
ance, ceftriaxone-calcium sludging is generally asymptom-
atic, but can result in frank cholelithiasis (i.e., gallstones)
[4]. The incidence of biliary sludging from ceftriaxone
ranges from 25% to 46%, serious complications rarely
occur [3].
Liver toxicity from acetaminophen, a common pediatric
antipyretic/analgesic is the most common cause of acute
liver failure in the USA [5]. Recommended pediatric acet-
aminophen dosing is 10–15 mg/kg every 4–6 hours with
daily maximum dose of 4 grams. Under normal hepatic
clearance, acetaminophen is principally conjugated to a
nontoxic glucuronide or sulfate. However, under conditions
of acetaminophen excess or disturbed metabolism, cyto-
chrome P450 2E1 can generate a reactive acetaminophen
intermediate, N-acetyl-p-benzoquinone imine (NAPQI),
which interacts with proteins and nucleic acids to damage
the liver [6]. As NAPQI is conjugated to glutathione and
renally excreted, acetaminophen overdose overwhelms
hepatic glutathione capacity leading to accumulation of
unconjugated NAPQI and hepatotoxicity [6]. Children ap-
pear to be less susceptible to acetaminophen toxicity than
adults because they have less capacity for oxidative metab-
olism [7].
Fenretinide (N-(4-hydroxyphenyl)retinamide; 4-HPR)
is a synthetic cytotoxic retinoid with chemopreventative
activity in animal models [8], and cytotoxic activity in a
variety of human cancer cell lines in vitro [9-11]. Oral
capsular fenretinide has a plasma half-life of ~15-20
hours [12]. Fenretinide is hepatically cleared, at least in
part, by cytochrome CYP3A4-dependent metabolism,
and glucuronidation by uridine 5’-diphospho-glucorony-
losyl transferases (UGTs). Three pediatric cancer clinical
trials of the capsule formulation (largely in neuroblast-
oma) reported minimal toxicity [12,13]. Grade 3–4 hep-
atic toxicities included hypoalbuminemia, and elevations
of AST, ALT, bilirubin, and alkaline phosphatase, which
resolved without sequelae. One patient developed fatal
hepatic failure determined on autopsy to be due to
massive tumor infiltration of the liver and felt to be
unrelated to fenretinide. However, tumor responses inthese trials were limited, possibly due to poor bioavail-
ability of the capsular formulation. Novel powder and
intravenous formulations have demonstrated improved
bioavailability as evidenced by higher plasma levels
[14,15]. A phase I study of the LXS powdered formula-
tion achieved plasma levels 2–6 fold higher than the
capsular formulation and four complete responses [14].
Hepatic toxicity was limited to grade 3 AST/ALT and
Grade 4 elevation of alkaline phosphatase which resolved
without sequelae.
The New Approaches to NeuroblastomaTherapy (NANT)
consortium conducted a Phase I trial of an intravenous
fenretinide emulsion formulation (IND#: 70058). We re-
port a case of fatal hepatic failure during course one of
therapy. After a thorough review of the clinical course,
concomitant medications, laboratory data, and fenretinide
plasma levels, we conclude that the event likely derived
from an unexpected multi-drug interaction between fenre-
tinide and ceftriaxone and acetaminophen.
Case presentation
The NANT 2004–03 Phase I study (ClinicalTrials.gov
Identifier NCT00646230) escalated the dose of intraven-
ous (IV) fenretinide (given for five days as a continuous
infusion and repeated every 21 days) using a standard
3 + 3 design to determine the maximum tolerated dose
(MTD). Toxicities were graded using the Common
Terminology Criteria for Adverse Events (CTCAE), ver-
sion 3.0. (http://ctep.cancer.gov). Eligible patients were ≤
30 years of age with relapsed/refractory high risk neuro-
blastoma. Organ function required included bilirubin,
AST, ALT, and creatinine ≤ 1.5 × normal. Plasma fenreti-
nide levels were obtained at hours 0, 6, 12, 24, 36,
48, 72, 96, 120 (end of infusion), then +2 hours and
+48 hours after the end of infusion, protected from
light, immediately frozen, and analyzed using an HPLC
method [16]. The study was terminated prior to deter-
mination of the MTD due to inadequate drug supply
after the enrollment of 17 patients. Table 1 summarizes
dose levels tested, dose limiting toxicities, and all hepatic
toxicities.
The patient was a seven year-old male diagnosed
with stage 4 high-risk neuroblastoma in October 2007,
who received induction according to the ANBL02P1
regimen (NCT00070200) which included cyclophospha-
mide, topotecan, cisplatin, etoposide, doxorubicin, and
vincristine [17] followed by myeloablative therapy with
I131-MIBG, carboplatin, etoposide, and melphalan with
autologous purged hematopoietic stem cell transplant in
May 2008 on NANT Protocol 2001–02 (NCT00253435).
He received 2160 cGy local radiation to the right adrenal
primary and distal femurs in July 2008, two courses
of 3 F8 anti-GD2 antibody, nine courses of isotretinoin,
and an additional 1440 cGy radiation to a single
















Dose Limiting Toxicity Total number courses/Hepatic toxicities (maximum














8.5 17.2 None 1 course: Gr 1 hypoalbuminemia, Gr 1 AST 1 dose 2 days
after Course 1




3 (3) 4.2 40.7 None 30 courses: Gr. 3 ALT, Gr 3 AST, Gr. 2 hypoalbuminemia, Gr 1
alkaline phosphatase. Got dose level 1 for courses 26–30




4.4 70.2 None 4 courses; Grade 1 AST




7 ( 6 ) 6.7 36.3 None 2 courses: Gr. 1 ALT, Gr 1 AST, Gr. 1 hypoalbuminemia 4 doses during
Course 3




9.7 60.7 Gr 4 hypertriglyceridemia due
to error in drug infusion
1 course: Not evaluable for dose escalation due to error in
drug infusion with 24 hour dose given over 12 hours; Gr 1
hypoalbuminemia, Gr 2 hyperbilirubinemia
11.4 33.0 Pseudotumor cerebri 1 course: Gr 3 ALT, Gr 2 AST
11 29.1 None 1 course; Gr 1 ALT, Gr 2 AST, Gr 1 hypoalbuminemia
5.3 23.7 None 2 courses: Gr 1 AST




2 (2) 5.5 83.3 Gr 4 epistaxis related to multi
organism non-neutropenic
bacteremia during course 5
5 courses: Gr 1 ALT, Gr 2 AST, Gr 2 hypoalbuminemia,





7.2 110.9 Fatal hepatic failure, renal
failure, and hypotension**
1 course (subject of this case report): Gr 5 liver dysfunction/
failure (clinical), Gr 4 ALT, Gr 4 AST, Gr 4 hyperbilirubinemia;
Gr 3 hypoalbuminemia; Gr 1 alkaline phosphatase









2 (0) 6.7 14.17# None 2 courses: Gr 1 ALT/Gr 1 AST
7.8 21.93# None 5 courses:Gr 1 AST, Gr 1 hypalbuminemia, Gr 1 alkaline
phosphatase
*Patient enrolled with Grade 1 hypoalbuminemia, resolved from asymptomatic Grade 3 to Grade 2 by day 27 of course; Grade 1 by Day 31 (definition of DLT was resolution to Grade 1 by Day 28). Dose level not
expanded since not considered clinically significant & protocol amended to exclude metabolic abnormalities as DLT. ** Subsequent Gr 4 acidosis, colitis, disseminated intravascular coagulation, enteritis, hypoxia, and



















Kang et al. BMC Research Notes 2014, 7:256 Page 4 of 7
http://www.biomedcentral.com/1756-0500/7/256persistent skull metastasis in July 2009. He then received
five courses of irinotecan and temozolomide for refrac-
tory bone metastases September-December, 2009. Bone
marrow exam done January 2010 showed recurrent tumor,
with no other relapse sites by CT or MIBG scans. No
additional anti-cancer therapy was received until the
intravenous fenretinide in February 2010 (assigned dose
1110 mg/m2/day as a continuous infusion for 120 hours).
The patient tolerated therapy without adverse events
until Day 4 when he developed fever (38.2°C) without
localizing symptoms. Acetaminophen (10 mg/kg) every
4 hours was initiated, and increased to 15 mg/kg begin-
ning with second dose. After blood cultures, intravenous
ceftriaxone was initiated. On the same day, temperature
increased to 39.4°C, despite acetaminophen and cooling
measures, with Grade 1 abdominal pain (had not stooled
in five days) and Grade 2 headache. Abdominal exam
was soft with normal bowel sounds. Neurologic exam
was normal and fundi without papilledema. The head-
ache was assessed as likely due to fever/dehydration but
pseudotumor cerebri from fenretinide could not be ruled
out, so infusion was stopped on Day 5 at Hour +119 of
the scheduled 120 hour infusion. Intravenous fluids were
given for poor oral intake and decreased urine output.
Acetaminophen and one dose of ibuprofen were given
for fever management. Two doses of ibuprofen were ad-
ministered Day 5. On the night of Day 5, headache im-
proved to Grade 1, but intermittent fever persisted and
abdominal pain increased to Grade 3. Abdominal plain
film was consistent with constipation.
Day 4 lab studies included an elevated LDH of 1241 U/L
(797 baseline), bilirubin 0.6 mg/dl (0.2 mg/dl baseline),
AST 57 U/L (39 U/L baseline), ALT 25 U/L (17 U/L base-
line). No labs were performed on the morning of Day 5.
On Day 5, the patient became hypotensive despite fluid
support and required pressor support (dopamine). Oxygen
saturation was 90% on room air but normal on mask oxy-
gen. Blood bacterial cultures from Days 4, 5, 6 and 7 and
fungal cultures from Day 6 were negative. On Day 6, AST
further elevated to 698 U/L, ALT elevated to 259 U/L, cre-
atinine was elevated at 1.6 mg/dL; LDH further elevated
to 4,231 U/L; and albumin was 2.6 g/dL. Day 6 abdominal
ultrasound showed renal echogenicity consistent with a
medical insult, and a gall stone with surrounding fluid.
Ceftriaxone was replaced on Day 6 with meropenem and
vancomycin; metronidazole was added Day 7. On Day 7,
the patient’s course steadily deteriorated with increasing
abdominal distention and pain requiring narcotics, with
new onset epistaxis. Abdominal X-rays showed paucity of
gas without free air. Mental status was diminished, but the
patient was arousable and verbal. A non-contrast head CT
was normal. Elective intubation was performed to main-
tain respiratory status. CT scan of the chest/abdomen/
pelvis showed marked hepatomegaly, moderate periportaledema, large bilateral pleural effusions and bibasilar atel-
ectasis without pulmonary infiltrates. Bilateral chest tubes
were required for the pleural effusions. Epinephrine and
vasopressin (stopped after 5 days) were added to dopa-
mine. Fever resolved on Day 7. On Day 8, the patient
developed anasarca and had paracentesis Days 8 and 10
(culture negative) for ascites. Laboratory results showed
progressive hepatic failure on Day 9 with secondary severe
metabolic acidosis and coagulopathy: ammonia 72 μM/L,
PT 24.7 sec, PTT 50 sec, fibrinogen 131, positive
D-Dimers, AST 8,289 U/L, ALT 1,588 U/L, bilirubin
3.5 mg/dL, albumin 2.8 g/dL, and elevated lactate
(101 mg/dL) with serum pH 7.17. Direct bilirubin was ele-
vated when evaluated (Days 13, 17–20), with maximum
of 9.3 mg/dL (indirect 12.6 mg/dL, total bilirubin 22.8
mg/dL) on Day 17. Skin biopsy (Day 14) of an erythema-
tous confluent macular rash progressing to desquamation
(onset Day 10) showed superficial perivascular and spon-
giotic dermatitis with eosinophils, consistent with either
drug eruption or viral exanthem. By Day 18, there was
worsening mucosal bleeding with frank blood from the
paracentesis site and chest tubes. The patient was anuric
by Day 20. Despite aggressive supportive care, the patient
expired Day 20. Of note, this patient previously received
ceftriaxone without hepatic toxicity or adverse reaction.
Other concomitant medications included montelukast and
ondansetron. Infectious evaluation included Influenza
virus A&B Rapid DAA (Day 5); negative quantitative PCR
for Epstein-Barr virus and cytomegalovirus (Day 6); Clos-
tridia difficile toxin A&B DAA, Escheria coli 0157 screen,
and stool adenovirus DAA (Day 8); negative respiratory
culture (Days 8,10), non-reactive Hepatitis A IgM, Hepa-
titis B Core antibody, Hepatitis B surface antigen and
reactive Hepatitis A IgG/IgM and Hepatitis B surface anti-
bodies (Day 13, had history of Hepatitis A and B vaccines);
and negative Acid Fast Bacilli, bacterial, viral, and fungal
cultures of ascites, urine, trachea, liver and spleen (post
mortem).
Autopsy showed extensive hepatocellular damage and
diffuse abdominal bleeding without evidence of tumor,
infection, or allergic reaction. Liver findings included
complete destruction of liver architecture with extensive
hemorrhagic necrosis of liver parenchyma, marked bile
duct proliferation, abundant hemosiderin consistent with
cholestasis; no viral inclusions and negative immuno-
histochemistry for Herpes Simples virus 1 and 2, and
cytomegalovirus. Post mortem skin biopsy showed
subepidermal bullae and extensive upper dermal acute
hemorrhage, likely a drug eruption since no evidence
of an infection. Left ventricular papillary muscle ne-
crosis was noted, likely contributing to circulatory fail-
ure and organ congestion. The autopsy was consistent
with drug-related hepatotoxicity as the primary fatal-
ity-inducing event. Hepatic function, and fenretinide
Kang et al. BMC Research Notes 2014, 7:256 Page 5 of 7
http://www.biomedcentral.com/1756-0500/7/256administration with plasma pharmacokinetics are sum-
marized in Figure 1. The death was considered definitely
related to fenretinide, but it remains unclear whether this
was related to fenretinide-alone (e.g. plasma levels or
total drug exposure) or to an interaction with other drugs
that may have affected the elimination of fenretinide or
acetaminophen (i.e., a hepato-biliary effect of ceftriaxone).
The onset of fever with elevated LDH and ALT on Day 4,
prior to starting ceftriaxone and acetaminophen, suggests
that some hepatocellular injury may have occurred with
fenretinide alone, but was likely exacerbated by these con-
comitant medications. The clinical generalized capillary
leakage seen in this patient has been reported with infec-
tion, drug injury, multi-organ failure, and rarely with other
retinoids [18].Time after infusion (hr)
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Figure 1 Plasma concentrations of fenretinide and its metabolites, co
analysis in patient. A) Plasma concentrations of fenretinide (closed circle)
triangle) versus time after the initiation of infusion (hr) is plotted. Each dose
the initial dose and 15 mg/kg for subsequent doses) is indicated. B) Liver f
are plotted on the same time scale. Due to the differences in values, the le
used for bilirubin and PT. A PT value at 40 hours was not available.While Grade 4 alkaline phosphatase elevations have oc-
curred in children treated with fenretinide capsular and LXS
oral power formulations, no alkaline phosphatase elevations
occurred in the other patients on the NANT intravenous
fenretinide study (Table 1). Grade 3 hypoalbuminemia in
one patient receiving intravenous fenretinide and was re-
ported in one patient receiving capsular fenretinide [13].
One fatal case of hepatic toxicity occurred in a seven year
old female on the ANBL0321 capsular fenretinide phase II
study at a dose of 2475 mg/m2/day for seven days, with on-
set 6 days after Course One, but extensive tumor infiltration
in the liver on autopsy was considered to be the etiology.
No other fatal hepatic toxicity has been reported on any
other adult or pediatric fenretinide study using the capsule,
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ncomitant ceftriaxone and acetaminophen, and laboratory
and the metabolites (4-MPR: open circle and 4-oxo-4-HPR: filled
of ceftriaxone (750 mg/dose), and acetaminophen (10 mg/kg for
unction analysis, AST/ALT, bilirubin (maximum for that date), and PT,
ft Y-axis was used for plotting AST and ALT, and right Y-axis was
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tients tolerated fenretinide plasma concentrations between
100–150 μM without hepatic toxicity. In this patient, fen-
retinide plasma concentrations gradually increased to
~60 μM at the end of Day 4. After acetaminophen and
ceftriaxone were started on Day 5, fenretinide plasma con-
centrations increased steeply to ~110 μM (Figure 1A).
Within two hours of stopping fenretinide, the fenretinide
level dropped to ~80 μM and, after two days, was less than
20 μM (Figure 1A). Peak fenretinide concentrations in two
other patients on this study were > 70 μM with minimal
toxicity (Table 1). Considering the minimal hepatic tox-
icity in all fenretinide studies, and the tolerance of higher
fenretinide plasma levels without hepatotoxicity, fenreti-
nide alone may not be the cause of hepatic failure in the
present case. Three other patients on the NANT 2004–03
study who received concomitant ceftriaxone all reported
transient grade 1–2 hepatic toxicities during that course
(Table 1). This may be due to inter-patient variation in
biliary sludging of ceftriaxone. Three other N2004-03
patients received concomitant acetaminophen without
hepatic toxicity; but no other patient received all three
drugs concomitantly. Also, peak plasma levels were vari-
able within a given dose, suggesting individual pharmaco-
genomics may play a role in the variation of plasma levels.
. In the present case, the fenretinide plasma level increased
sharply after ceftriaxone and acetaminophen were initi-
ated. Retrospective attempts to measure acetaminophen
levels in the fenretinide PK samples were not informative
since the samples were beyond the stability duration of
acetaminophen. Based on the abrupt decrease of fenreti-
nide clearance, we hypothesize that acetaminophen clear-
ance was also reduced due to the concurrent ceftriaxone.
It is unclear whether acute liver failure would have been
due to altered pharmacokinetics of acetaminophen or to
hepatic glutathione depletion. Based on a previous report,
intracellular glutathione levels are not related to fenreti-
nide cellular cytotoxicity in vitro, suggesting that fenreti-
nide may not affect intracellular glutathione [19]. In
addition, N-(4-methoxyphenyl)retinamide (4-MPR) is the
major metabolite of fenretinide and is a methylation
(phase II metabolism) product eliminated without further
modification. Therefore, it is less likely that acetamino-
phen and fenretinide competed for glutathione - competi-
tion for UGT-mediated glucuronidation is more likely.
This case suggests that the biliary sludging effect of
ceftriaxone may have interfered with the elimination of
fenretinide and acetaminophen, resulting in an unex-
pected adverse and severe acetaminophen toxicity. How-
ever, ibuprofen-related hepatic failure cannot be ruled out
as it is reported that therapeutic doses of ibuprofen as a
single agent can result in acute liver failure [20].
After this event, NANT 2004–03, and related adult tri-
als, PhI-42 (NCT00104923) and PhI-54 (NCT00387504),were amended to prohibit ceftriaxone or acetaminophen
for 24 hours prior to the fenretinide infusion and for
24 hours (ceftriaxone) or 48 hours (acetaminophen) after
fenretinide infusion completion, with ibuprofen recom-
mended (if needed) for fever during the fenretinide
infusion. After enrolling two patients following this amend-
ment, the NANT 2004–03 trial closed secondary to insuffi-
cient drug supply prior to determining an MTD.
Conclusion
This clinical case reports lethal hepatotoxicity in a
patient concurrently receiving intravenous fenretinide,
ceftriaxone, and acetaminophen. The event is suspected
to result from an unexpected drug interaction between
these three agents resulting in hepatic acetaminophen
toxicity. Although the prevalence of cholestasis with
ceftriaxone usage is relatively high, the potential drug
interaction with these concomitant medications has not
been previously reported. Concomitant use of fenreti-
nide, ceftriaxone, and acetaminophen should be avoided.
Consent
Written informed consent was obtained from the patient’s
guardian for publication of this Case Report and any
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